HEB - Hemispherx Biopharma, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue36743792133
Cost of Revenue8841,1831,1081,598
Gross Profit-517-746-1,016-1,465
Operating Expenses
Research Development4,7374,0914,9737,823
Selling General and Administrative6,2016,5726,8317,147
Non Recurring----
Others----
Total Operating Expenses11,82211,84612,91216,568
Operating Income or Loss-11,455-11,409-12,820-16,435
Income from Continuing Operations
Total Other Income/Expenses Net1,6423,1505,3181,205
Earnings Before Interest and Taxes-11,455-11,409-12,820-16,435
Interest Expense-502-139-139-3
Income Before Tax-9,813-8,259-7,502-15,230
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-9,813-8,259-7,502-15,230
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-9,813-8,259-7,502-15,230
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-9,813-8,259-7,502-15,230